Alcon Inc. Ordinary Shares (ALC) Analyst Ratings & Price Targets

Alcon Inc. Ordinary Shares

ALC · NYSE

Analyst Consensus

Buy

19 analysts

$68

Current

—

Low

$85

Average

—

High

Average target implies +25.48% versus the current price.

Analyst Ratings Synthesis

Consensus is Buy, backed by 19 analysts, with a mean price target of $85.5. The supplied consensus record gives no low or high target, so the target range and the breadth of disagreement cannot be measured. It also names neither the most bullish nor least bullish analyst and provides no firm-level target dispersion. No analyst ratings, price targets, or revisions are explicitly reported during the past week, so the direction of revisions is unavailable. The substantive disagreement appears unobservable in the supplied data: the evidence shows a positive consensus and a mean target but does not identify differing earnings, valuation, operating, or risk assumptions behind that view.

Rating Actions

No individual rating actions have been captured for ALCyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

ARGUS RESEARCH

B OF A GLBL RES

BAIRD R W

BTIG

CITIGROUP

CO FORECST

JEFFERIES & CO.

JP MORGAN SECUR

MIZUHO SECURITI

MORGAN STANLEY

NEEDHAM & CO.

OPPENHEIMER HLD

ROTHSCHILD REDB

SANFORD BERNSTE

SOCIETE GENERAL

STIFEL NICOLAUS

UBS

WELLS FARGO SEC

ZACKS RESEARCH

Symbol: ALC
Type: Stock
Sector: Health Care
Industry: Ophthalmic Goods
Exchange: NYSE

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries and territories each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

Key Issues

Bullish view

Alcon’s upcoming quarter ended June 2026 is receiving specific attention to performance measures beyond headline revenue and earnings, suggesting operating metrics could provide a positive catalyst.

Bearish view

No Q2 results, estimates, or quantified operating metrics are supplied, so the evidence does not establish that Alcon will beat expectations or support the recent share rebound.

Analyst Consensus

See all

Buy

19 analysts

$68

Current

—

Low

$85

Average

—

High

Average target implies +25.48% versus the current price.

Earnings History

BeatMissNo estimate

Alcon Inc. Ordinary Shares

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers